See more : The Aaron’s Company, Inc. (AAN) Income Statement Analysis – Financial Results
Complete financial analysis of Aridis Pharmaceuticals, Inc. (ARDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aridis Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Guizhou Taiyong-Changzheng Technology Co.,Ltd. (002927.SZ) Income Statement Analysis – Financial Results
- O.B.System Inc. (5576.T) Income Statement Analysis – Financial Results
- Beijing Haitian Ruisheng Science Technology Ltd. (688787.SS) Income Statement Analysis – Financial Results
- Alamos Gold Inc. (0UGS.L) Income Statement Analysis – Financial Results
- Volkswagen AG (VOW3.DE) Income Statement Analysis – Financial Results
Aridis Pharmaceuticals, Inc. (ARDS)
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.00M | 1.02M | 2.76M | 860.00K | 2.27M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.93M |
| Gross Profit | 0.00 | 0.00 | 1.00M | 1.02M | 2.76M | 860.00K | 342.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 15.07% |
| Research & Development | 25.92M | 37.94M | 16.96M | 24.08M | 23.00M | 17.44M | 6.26M |
| General & Administrative | 7.16M | 7.31M | 6.45M | 6.03M | 3.87M | 3.16M | 1.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.16M | 7.31M | 6.45M | 6.03M | 3.87M | 3.16M | 1.97M |
| Other Expenses | -3.09M | -1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.99M | 43.71M | 23.40M | 30.11M | 26.87M | 20.60M | 8.23M |
| Cost & Expenses | 29.99M | 43.71M | 23.40M | 30.11M | 26.87M | 20.60M | 10.15M |
| Interest Income | 0.00 | 0.00 | 77.00K | 357.00K | 0.00 | 234.00K | 0.00 |
| Interest Expense | 378.00K | -245.00K | 0.00 | 0.00 | 420.00K | 0.00 | 366.00K |
| Depreciation & Amortization | 487.00K | -722.00K | 337.00K | 338.00K | 283.00K | 62.00K | 23.00K |
| EBITDA | -29.51M | -44.43M | -22.06M | -28.75M | -23.83M | -19.68M | -7.86M |
| EBITDA Ratio | 0.00% | 0.00% | -2,240.10% | -2,846.09% | -933.95% | -1,688.84% | -338.87% |
| Operating Income | -29.99M | -43.71M | -22.40M | -29.09M | -24.12M | -19.74M | -7.88M |
| Operating Income Ratio | 0.00% | 0.00% | -2,240.10% | -2,846.09% | -874.76% | -2,295.12% | -347.47% |
| Total Other Income/Expenses | -378.00K | 1.52M | 68.00K | -594.00K | 2.01M | -4.92M | -538.00K |
| Income Before Tax | -30.37M | -43.19M | -22.33M | -29.68M | -22.11M | -24.66M | -8.42M |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,233.30% | -2,904.21% | -801.78% | -2,866.98% | -371.18% |
| Income Tax Expense | 378.00K | -912.00K | -414.00K | -695.00K | 2.43M | 4.92M | 538.00K |
| Net Income | -30.75M | -42.28M | -21.92M | -28.99M | -22.11M | -24.66M | -8.42M |
| Net Income Ratio | 0.00% | 0.00% | -2,191.90% | -2,836.20% | -801.78% | -2,866.98% | -371.18% |
| EPS | -1.64 | -3.44 | -2.39 | -3.43 | -7.02 | -3.12 | -1.07 |
| EPS Diluted | -1.64 | -3.44 | -2.39 | -3.43 | -7.02 | -3.12 | -1.07 |
| Weighted Avg Shares Out | 18.78M | 12.29M | 9.17M | 8.46M | 3.15M | 7.89M | 7.89M |
| Weighted Avg Shares Out (Dil) | 18.78M | 12.29M | 9.17M | 8.46M | 3.15M | 7.89M | 7.89M |
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
5 Hot Penny Stocks To Watch With Big News This Week
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing
Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates
Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop
5 Short Squeeze Candidate To Watch: Aridis Pharmaceuticals Tops List, EVgo, Indonesia Energy Corp And More
Source: https://incomestatements.info
Category: Stock Reports